SLC5A2 and heart failure: In a meta-analysis of all available pivotal RCTs of SGLT2 inhibitors in 21,947 participants with heart failure, SGLT2 inhibitors showed a consistent relative risk reduction on the composite of CV death or first HHF in participants with an HHF within 12 months of randomization (HR 0.72, 95% CI: 0.65-0.80) vs in participants without an HHF within 12 months (HR: 0.80, 95% CI: 0.73-0.87; P for interaction = 0.52).13